Shinobi Therapeutics
Developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€185—278m (Dealroom.co estimates Dec 2023.)
South San Francisco California (HQ)
Authorizing premium user...